Navigation Links
Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Date:11/4/2007

Study Supports Dose-dependent Activity of Antidote Component

ORLANDO, Fla., Nov. 4 /PRNewswire/ -- Regado Biosciences today presented data from a randomized, double-blind, placebo-controlled Phase Ic study of the Company's REG1 Anticoagulation System. REG1 is a two-component system comprised of an aptamer-based anticoagulant, RB006, and its matched antidote, RB007, which binds to and neutralizes RB006. The study results support RB007's ability to reverse the anticoagulant effect of RB006 either completely or partially, depending on the level of dosing of RB007. Consistent with previously reported Phase I results, these data were presented by the Duke Clinical Research Institute at the American Heart Association's 2007 Scientific Sessions, currently being held in Orlando, Florida.

Clinical researchers from the Duke Clinical Research Institute and Regado randomized 39 healthy volunteers to receive either three consecutive REG1 treatment cycles or placebo. Each REG1 cycle consisted of an intravenous (IV) bolus of RB006 dosed at 0.75 mg/kg, followed an hour later by a descending dose of RB007, ranging from a 2:1 to 0.125:1 antidote:drug ratio (1.5 mg/kg to 0.094 mg/kg of RB007). Clinical and coagulation assessments were measured for 14 days.

The study showed repeated doses of RB006 achieved highly reproducible increases in activated partial thromboplastin time (aPTT), a well-accepted surrogate marker of the blood's ability to clot. Subsequently, repeat doses of RB007 reversed the aPTT levels dose-dependently and reproducibly. There were no major bleeding episodes or other serious adverse events reported in this study.

"I am encouraged by RB007's activity to date in reversing or neutralizing the anticoagulant effect of RB006, either completely or partially, as needed. The potential to modulate coagulation quickly based on the patient's condition represents an advance in anticoagulation therapy that could advance clinical care," said Ro
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
(Date:5/22/2015)... , May 22, 2015 Electrophysiologist Kevin ... recently traveled to Boston, MA ... the 2015 Heart Rhythm Society conference. These scientific ... focus on the ideas, people and technology that ... is a hybrid, minimally invasive cardiac operation that ...
(Date:5/22/2015)... 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a ... and regeneration, today announced that J.J. Finkelstein , ... a corporate overview at two upcoming investor conferences. ... 4 th Annual Microcap Conference on Thursday May ... at 11:00 am EDT.  A webcast will be ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3
... Feb. 1, 2011 Reportlinker.com announces that a new ... Personalized Medicine - scientific & commercial ... Summary The aim of ... right drug to the right patient and, in some ...
... of Dermatology, Laser and Cosmetics is now offering Alma Lasers ... Boerne area to treat superficial vascular and pigmented irregularities and ... add this new service for our patients," said Dr. Ghohestani, ... a long time provider of aesthetic medicine, we wanted to ...
Cached Medicine Technology:Reportlinker Adds Personalized Medicine - Scientific & Commercial Aspects 2Reportlinker Adds Personalized Medicine - Scientific & Commercial Aspects 3San Antonio's Texas Institute of Dermatology, Laser and Cosmetics Adds Alma Lasers Harmony XL Cosmetic Laser to Offer Advanced Rejuvenation Treatments to Patients 2
(Date:5/24/2015)... Geneva, WI (PRWEB) May 24, 2015 ... Mercy Health System CEO - ... principal and honored at the fourth ... held April 15 at Geneva National ... (by school): ,     -Badger High School, ...
(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
(Date:5/23/2015)... Javon Bea Mercy Health System CEO ... Center, 557 N. Washington St., Janesville, will host an ... pm. , The 8-week clinic is lead by Brent ... who will offer training that encompasses a warm-up, training ... show selection and weekly training plans. , The program ...
(Date:5/22/2015)... The American College of Traditional Chinese Medicine ... will hold a webinar on the updates of the ... Classical Chinese Medicine. , Webinar – First Professional Doctorate ... Dean of Clinical Education, will lead this webinar in ... program. ACTCM is currently developing this degree program based ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at ... the 2015 Congress of Future Medical Leaders in Boston, ... of “America’s highest achieving high school students.” , “I’m ... new goals and learn better study habits,” said Omar. ... which we can ask the surgeons questions.” , The ...
Breaking Medicine News(10 mins):Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2
... French . , Toronto (March 16, 2011) ... received $16 million in funding. The studies, co-funded by the ... Agency (CSA), were announced today at the University of Toronto ... Jane Aubin, Scientific Director of the Canadian Institutes of Health ...
... WEDNESDAY, March 16 (HealthDay News) -- The brain structure of ... a new study. Some of these differences may be ... are likely to be present from birth, said the team ... in the study of phonetics and are able to distinguish ...
... A research article co-authored by Brenna Anderson, MD, director ... Maternal-Fetal Medicine at Women & Infants Hospital of Rhode ... of the American Journal of Reproductive Immunology . ... on the human immunodeficiency virus (HIV) that took place ...
... HealthDay Reporter , WEDNESDAY, March 16 (HealthDay News) ... their health benefits during the recession often had no way ... at risk of financial ruin, according to a new report ... the recession catapulted 9 million more Americans -- or ...
... New York, NY, March 16, 2011An estimated nine million ... a job that was lostbecame uninsured in the last two ... Survey, released today. The survey paints a bleak picture for ... they or their spouse lost a job in the past ...
... HealthDay Reporter , TUESDAY, March 15 (HealthDay News) -- ... blood levels of phosphorous, calcium and parathyroid hormone, to assess ... of research stretching back more than 60 years casts doubt ... found little evidence to support the notion that these "biomarkers" ...
Cached Medicine News:Health News:Important funding for nanomedicine research to improve diagnosis and treatment 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 3Health News:Brains of Phonetics Experts Differ From Those of General Public 2Health News:HIV research included in journal 2Health News:Report: Unemployment Adds 9 Million Uninsured in U.S. 2Health News:Report: Unemployment Adds 9 Million Uninsured in U.S. 3Health News:Report: Unemployment Adds 9 Million Uninsured in U.S. 4Health News:New health insurance survey: 9 million adults joined ranks of uninsured due to job loss in 2010 2Health News:New health insurance survey: 9 million adults joined ranks of uninsured due to job loss in 2010 3Health News:New health insurance survey: 9 million adults joined ranks of uninsured due to job loss in 2010 4Health News:New health insurance survey: 9 million adults joined ranks of uninsured due to job loss in 2010 5Health News:Study Questions Tests Used to Spot Heart Risks in Kidney Patients 2Health News:Study Questions Tests Used to Spot Heart Risks in Kidney Patients 3
SunGlide™ Stylette - Blue Neonatal. Use in 2.0 to 3.5mm tubes. 25/box....
Hollow Copper Tube with Suction Port 16.5....
Surgical Stainless Steel Adult 16.5....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Medicine Products: